Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5393457 | 1.00 | ADORA1 (0.58) | ADORA1SLC29A1ABL1RIN1PMP22 | |
| SCHEMBL5393549 | 0.92 | ADORA1 (0.56) | ADORA1SLC29A1PMP22ADORA3GAA | |
| SCHEMBL5386740 | 0.92 | ADORA1 (0.56) | ADORA1SLC29A1PMP22ADORA3GAA | |
| SCHEMBL5394711 | 0.91 | ADORA1 (0.54) | ADORA1SLC29A1 | |
| SCHEMBL5394715 | 0.91 | ADORA1 (0.54) | ADORA1SLC29A1 | |
| SCHEMBL5393601 | 0.91 | ADORA1 (0.56) | ADORA1SLC29A1PMP22ADORA3GAA | |
| SCHEMBL5393630 | 0.91 | ADORA1 (0.56) | ADORA1SLC29A1PMP22ADORA3GAA | |
| SCHEMBL5394541 | 0.91 | ADORA1 (0.57) | ADORA1SLC29A1ABL1RIN1ADORA3 | |
| SCHEMBL5394546 | 0.91 | ADORA1 (0.57) | ADORA1SLC29A1ABL1RIN1ADORA3 | |
| SCHEMBL5393015 | 0.90 | ADORA1 (0.56) | ADORA1SLC29A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163928-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2007-01-16 | — | — | US | claimed |
| JP-2006516641-A | — | — | 2006-07-06 | — | — | JP | claimed |
| EP-1590359-A2 | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS | CV Therapeutics Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| US-20040198691-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2004-10-07 | — | — | US | claimed |
| WO-2004069185-A2 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS INC. (US) | 2004-08-19 | — | — | WO | claimed |
| US-7163928-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20040198691-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198691-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885SLC29A1 410/4885ABL1 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.